Description:
Researchers have developed a novel formulation strategy to encapsulate molecules, including but not limited to histone deacetylase inhibitor (HDACi) drugs in nanoparticle networks composed of beta-cyclodextrin-poly(beta-amino esters). Advantages of this system include high loading capacity, increased in vivo tolerability, sustained release, and improved drug distribution and activity in the treatment of solid tumors.
Technology Overview
A beta-cyclodextrin-based, cross-linked polymer is employed in the formulation as a novel excipient instead of conventional diblock copolymers like PLGA and PLA-PEG. This pre-synthesized polymeric network forms particles in aqueous medium that are in the range of 100-500nm with defined polydispersity. Simply doping the drug at a desired concentration, followed by mechanical agitation, leads to the formulation of drug bound nanoparticles through self-assembly. The particles can then be retrieved and concentrated with subsequent lyophilization.
Benefits/Technology Advantages
- Simpler loading strategy compared to previously studied techniques that does not require physical manipulation to optimize (i.e. no temperature or pH changes needed)
- Higher drug loading capability per nanoparticle (8 wt% or more in terms of drug to excipient ratio)
- Novel mechanisms of drug loading and release are a particular benefit to drugs with ionizable moieties
- Unique surface chemistry improves modularity of the system for further engineering, including attachment of surface targeting ligands or imaging agents
Potential Applications
- Sustained drug release
- Oncology, Neuro-oncology, Trauma, Inflammation, Neuro-Immunology, Neurodegeneration, HIV/AIDs, Cardioprotection
Lead Inventor
Rachael Sirianni, Ph.D.: Her research is focused on the development and translation of novel therapeutics for the treatment of pediatric brain tumors.
Intellectual Property Status
- PCT application filed: PCT/US2020/024627
- Available for licensing worldwide, exclusive or non-exclusive
Relevant Publication:
Stage of Development
Pre-clinical
UTHealth Ref. No.: 2019-0034